Glossy Full Color Sandstone
HER2 Inactive Tyrosine Kinase
Made by
Print With Shapeways
Choose Your Size
Choose Your Material
Choose your color and finish
Choose Your Size
$99.00
Choose Your Material
Choose your color and finish
Have a question about this product?
contact the designerYou must be logged in and verified to contact the designer.
Product Description
Model Description
This protein model of HER2 bound by TAK-285 is colored according to the protein's bFactor and created from PDB ID: 3RCD
Protein Description
Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been investigated for breast, lung, gastric, prostate, and other cancers; one, lapatinib, is currently approved for breast cancer. To develop novel HER2/EGFR dual kinase inhibitors, we designed and synthesized pyrrolo[3,2-d]pyrimidine derivatives capable of fitting into the receptors' ATP binding site. Among the prepared compounds, 34e showed potent HER2 and EGFR (HER1) inhibitory activities as well as tumor growth inhibitory activity. The X-ray cocrystal structures of 34e with both HER2 and EGFR demonstrated that 34e interacts with the expected residues in their respective ATP pockets. Furthermore, reflecting its good oral bioavailability, 34e exhibited potent in vivo efficacy in HER2-overexpressing tumor xenograft models. On the basis of these findings, we report 34e (TAK-285) as a promising candidate for clinical development as a novel HER2/EGFR dual kinase inhibitor.
https://www.rcsb.org/structure/3rcd
This protein model of HER2 bound by TAK-285 is colored according to the protein's bFactor and created from PDB ID: 3RCD
Protein Description
Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been investigated for breast, lung, gastric, prostate, and other cancers; one, lapatinib, is currently approved for breast cancer. To develop novel HER2/EGFR dual kinase inhibitors, we designed and synthesized pyrrolo[3,2-d]pyrimidine derivatives capable of fitting into the receptors' ATP binding site. Among the prepared compounds, 34e showed potent HER2 and EGFR (HER1) inhibitory activities as well as tumor growth inhibitory activity. The X-ray cocrystal structures of 34e with both HER2 and EGFR demonstrated that 34e interacts with the expected residues in their respective ATP pockets. Furthermore, reflecting its good oral bioavailability, 34e exhibited potent in vivo efficacy in HER2-overexpressing tumor xenograft models. On the basis of these findings, we report 34e (TAK-285) as a promising candidate for clinical development as a novel HER2/EGFR dual kinase inhibitor.
https://www.rcsb.org/structure/3rcd
Details
What's in the box:
Mdm: her2_3poz_aloop_4hjo
Dimensions:
Success Rate:
First To try.
What's this?
Rating:
Mature audiences only.
